Accelerated Radiation Therapy for Glioblastoma
Trial Summary
Do I need to stop my current medications for this trial?
The trial protocol does not specify whether you need to stop taking your current medications. However, if you are taking carbidopa/levodopa, you must stop at least 48 hours before an 18F-DOPA-PET scan.
What data supports the effectiveness of Accelerated Hypofractionated Radiation Therapy for glioblastoma?
Research shows that hypofractionated radiation therapy, which involves giving larger doses of radiation over a shorter period, can be effective for glioblastoma, especially in elderly or frail patients. It has been found to be as effective as traditional longer courses of radiation, with the added benefit of a shorter treatment time.12345
Is accelerated radiation therapy safe for humans?
Accelerated radiation therapy, also known as hypofractionated radiation therapy, has been found to be a safe treatment option for glioblastoma patients, including those who are elderly or have other health challenges. While there is a risk of increased toxicity in some cases, studies have shown that most patients tolerate the treatment well, and it is considered a feasible option.14678
How is Accelerated Hypofractionated Radiation Therapy different from other treatments for glioblastoma?
Accelerated Hypofractionated Radiation Therapy is unique because it delivers higher doses of radiation over a shorter period, which can be more convenient for patients and may reduce treatment time without compromising effectiveness or increasing side effects compared to standard radiation therapy.12349
What is the purpose of this trial?
This phase II trial compares the effect of short course radiotherapy (RT) to standard course RT for the treatment of patients diagnosed with glioblastoma (GBM). The researchers want to learn whether the shorter course treatment is non-inferior (not worse than the standard of care), for patients with GBM. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Short course radiotherapy delivers higher doses of radiation over a shorter period of time and may kill more tumor cells and have fewer side effects.
Research Team
Roman O. Kowalchuk, MD
Principal Investigator
Mayo Clinic in Rochester
William G. Breen, M.D.
Principal Investigator
Mayo Clinic in Rochester
Eligibility Criteria
This trial is for adults over 18 with confirmed glioblastoma, able to complete questionnaires and have an ECOG performance status of 3 or less. Participants must consent in writing, be willing to follow up at the enrolling institution, and have a postoperative tumor size ≤6 cm. Excluded are those with IDH mutation tumors, MRI/18F-DOPA-PET scan issues, certain medication use, not receiving radiation at specified locations, or unwilling to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients undergo either short course RT for 5-10 fractions over 1-2 weeks or standard course RT for 15-30 fractions over 3-6 weeks, with concurrent temozolomide administration
Adjuvant Therapy
Patients receive temozolomide on days 1-5 every 28 days for up to 5-6 cycles post-radiation
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Accelerated Hypofractionated Radiation Therapy
Accelerated Hypofractionated Radiation Therapy is already approved in United States, European Union for the following indications:
- Glioblastoma
- Glioblastoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor